Sanwa Kagaku Kenkyusho Releases SEIBULE, Miglitol Agent for Controlling Postprandical Blood Glucose.Tokyo, Japan, Jan 11, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Sanwa Kagaku Kenkyusho will begin distributing SEIBULE Tablet 25mg/50mg/75mg, its proprietary ethical drug for treating diabetes, on January 11. The new product, which is made of miglitol, is indicated for reducing postprandial postprandial /post·pran·di·al/ (-pran´de-al) occurring after a meal. post·pran·di·al adj. Following a meal, especially dinner. blood glucose levels blood glucose level, n level of glu-cose in the bloodstream, normally about 70 to 115 mg/dL after fasting overnight. Higher levels may indicate diseases such as diabetes mellitus. in type 2 diabetics. Sanwa Kagaku and Dainippon Sumitomo Pharma plan to jointly promote the new product. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion